Oxford Biomedica---Die neue Genentech - 500 Beiträge pro Seite

[BrauchGeld]

Hallo

Ich hatte die Aktie schon mal vorgestellt leider ist der Thread historisch geworden.
Der Kurs von Oxford Bio wurde durch die aktuelle Kapitalerhöhung in die knie gezwungen was sich hervorragend für ein einstieg bietet.
An der Heimatbörse ist die Aktie sehr stark gefragt.
Ich denke hier wird es bald wieder aufwärst gehen.
Für mich ist Oxford Bio das Top unternehmen in der Krebsforschung.


Oxford Biomedica
Kurs:26,25p~~~0,39€
Marktkap:97,87mio pfund~~~~145mio€





Präsentation Sep 05:
http://www.oxfordbiomedica.co.uk/pdfs/presentation.pdf

MAJOR SHAREHOLDERS

Notifier Holding

Alan Kingsman 17,032,590

Alan G Goodman 5,083,000

Andrew Wood 198,022

Peter Nolan 147,738

Peter Johnson 100,000

Doug Jolly 50,000

[BrauchGeld]

In Kürze:

Start Phase3 TroVax
Partner für TroVax

TODAY ON PHARMALIVE.COM

Oxford Biomedica Announces Progress with Registration Plan and Partnership Discussions for Trovax, and Proposed Institutional Placing and Open Offer Alongside $5 Million Investment by Sigma-Aldrich

OXFORD, England, November 2, 2005 – Oxford BioMedica (LSE: OXB), the leading gene therapy company, announces progress with its registration plan and details of a Phase III trial with its lead cancer immunotherapy, TroVax, in renal cell carcinoma; provides further guidance on the status of partnership discussions for TroVax; and provides clarification of press speculation regarding a proposed fund raising.

The Company plans to initiate a Phase III trial with TroVax in renal cell carcinoma (RCC) during 2006. TroVax has the potential to be used for the treatment of most solid tumours, targeting a market that currently exceeds $15 billion.

[BrauchGeld]

Die grossen haben sich auch schon kräftig mir Oxford aktien eingedeckt.


Mehr Infos hier:
http://moneyextra.uk-wire.com/cgi-bin/index?search_type=3&wo…

[BrauchGeld]

Wie auch auf der Pipeline zusehen ist hat sich Oxford nicht nur auf Krebs spezalisiert.

Gentherapie gegen Muskellähmung

Krankheitsausbruch bei Mäusen verzögert
Sabine Behrends

Mit einer Gentherapie haben britische und belgische Wissenschaftler bei Mäusen den
Beginn der Muskelkrankheit ALS deutlich hinausgezögert. Wie Mediziner um Mimoun
Azzouz von der Firma Oxford BioMedica im Fachmagazin Nature berichten, lebten die
gentherapeutisch behandelten Tiere zudem fast ein Drittel länger als unbehandelte
Vergleichstiere. Damit sei die nun erprobte Therapie eine der effektivsten derzeit
bekannten Behandlungsformen der ALS.

Bei der amyotrophen Lateral- sklerose, kurz ALS, sterben bestimmte Nervenzellen ab,
die Bewegungssignale aus dem Gehirn an die Muskeln weiterleiten. Da von der
fortschreitenden Muskellähmung auch die Atemmuskulatur betroffen ist, leben die
meisten Patienten nur noch wenige Jahre nach dem Auftreten der ersten Symptome.

Mimoun Azzouz und seine Kollegen nahmen ihre Versuche an Mäusen vor, die eine
Veranlagung für ALS haben. Sie schleusten in die Tiere gentechnisch veränderte
Lentiviren, die sie zuvor mit der Erbinformation für den so genannten vaskulären
endothelialen Wachstumsfaktor (VEGF) ausgestattet hatten. Die Forscher injizierten
die Viren in mehrere Muskeln von wenige Wochen alten Tieren, die noch keine
ALS-Symptome zeigten. Von den Muskeln aus drangen die Viren selbstständig in die dort
ankommenden Nervenzellen ein und veranlassten sie VEGF zu produzieren.

Die unbehandelten ALS-Mäuse entwickelten bereits nach 95 Tagen erste Symptome, bei
den mit VEGF behandelten Tieren begann die Muskelschwäche erst nach 123 Tagen. Selbst
bei Tieren, die die Forscher erst nach dem Auftreten der ersten Symptome behandelten,
erwies sich VEGF noch als wirksam: Die Krankheit schritt bei ihnen deutlich langsamer
voran, und die Lebensspanne nahm zu. Weil die Gentherapie bei den Mäusen keinerlei
Nebenwirkungen verursachte, hoffen Azzouz und seine Kollegen, dass die Methode eines
Tages auch die Muskelschwäche bei ALS-Patienten lindern kann.

[BrauchGeld]

IMMEDIATE RELEASE 12 DECEMBER 2005

OXFORD BIOMEDICA ANNOUNCES RESULT OF
EXTRAORDINARY GENERAL MEETING

Oxford, UK: 12 December 2005 - Oxford BioMedica (LSE: OXB) announced today that
at its Extraordinary General Meeting (`EGM`), held today in London, all
resolutions were duly passed. The resolutions put to shareholders approve the
fully underwritten Placing and Open Offer (the `Issue`) and an investment by
Sigma-Aldrich (the `Subscription`), announced on 16 November 2005, to raise
£30.1 million (approximately £28.0 million net of expenses). Pursuant to the
Issue and the Subscription, an aggregate of 120,328,041 new Ordinary Shares will
be issued at 25 pence per share.

The Placing and Open Offer comprised 108,800,000 new Ordinary Shares. Qualifying
Shareholders were invited to participate in the Issue by way of the Open Offer
of up to 27,007,869 of these new Ordinary Shares on the basis of 1 Open Offer
Share for every 14 Existing Ordinary Shares held on the Record Date and so in
proportion to any number of Existing Ordinary Shares then held and such further
numbers in excess of their Basic Entitlement as could be satisfied, to the
extent that other Qualifying Shareholders did not take up their Basic
Entitlement.

The Open Offer closed at 3.00 p.m. on 9 December 2005, by which time valid
applications had been received in respect of 21,752,507 Open Offer Shares,
representing approximately 80.54 per cent. of the Open Offer Shares available
under the Open Offer. The remaining 5,255,362 Open Offer Shares and the
81,792,131 Placing Shares will now be subscribed for by institutional and other
investors with whom they were placed in terms of the Placing Agreement.

Sigma-Aldrich (NASDAQ: SIAL), a life sciences company, has invested £2.9 million
at the Issue Price, by subscribing for 11,528,041 new Ordinary Shares, alongside
the Placing and Open Offer. This investment is being made as part of a strategic
alliance, announced on 20 October 2005, which provides Sigma-Aldrich with an
exclusive licence to commercialise Oxford BioMedica`s LentiVector(R) technology
for the reagent and research tool market.

The Placing and Open Offer and the Subscription remain conditional upon
admission of the New Ordinary Shares and the Subscription Shares to the Official
List of the UK Listing Authority and to trading on the London Stock Exchange`s
market for listed securities (`Admission`). It is expected that Admission and
dealings in the New Ordinary Shares and the Subscription Shares will commence on
8.00 a.m. on 15 December 2005.

CREST stock accounts are expected to be credited on 15 December 2005 in respect
of New Ordinary Shares to be held in uncertificated form and definitive share
certificates in respect of New Ordinary Shares to be held in certificated form
are expected to be posted, where applicable, by 22 December 2005.

Including the net proceeds from the Placing and Open Offer and the Subscription,
the Company`s pro-forma net cash balance at 30 June 2005 was approximately £47
million.

Unless the context provides otherwise, words and expressions defined in the
prospectus sent to Shareholders dated 16 November 2005 shall have the same
meanings in this announcement.

Commenting on the results of the EGM, Professor Alan Kingsman, Oxford
BioMedica`s Chief Executive, said: `We are very pleased to have completed this
Placing and Open Offer with strong support from both our existing and new
investors. Furthermore, we look forward to a successful relationship with our
strategic corporate investor, Sigma-Aldrich. The new funds will enable the
Company to initiate a Phase III trial with TroVax, our lead cancer
immunotherapy, and negotiate with commercial partners from a position of
strength.`

Professor Kingsman continued: `Discussions with the FDA regarding our plans for
TroVax development have been helpful and encouraging. On advice from the FDA,
the Company plans to submit an application for a Special Protocol Assessment in
early 2006. This will be a Phase III randomised survival study comparing TroVax
to placebo in approximately 700 patients with metastatic renal cancer.
Recruitment is scheduled to begin in August 2006 and the data are expected to
support registration for this first indication in 2009. We look forward to
working with the FDA on the Special Protocol Assessment. This process and the
start of the Phase III trial represent significant milestones for Oxford
BioMedica.`

`TroVax is now a Phase III product, MetXia is in Phase II development for
pancreatic cancer and a further three products are expected to enter clinical
development in 2006. With the pipeline showing progress across all programmes,
opportunities for commercial collaborations, and now a strengthened balance
sheet, I believe that the Company can deliver significant value for
shareholders.`

[BrauchGeld]

Nabend

Wie man sieht hat UBS innerhalb der letzten woche knapp 1mio aktien zusätzlich gekauft.


Oxford Biomedica PLC
12 December 2005


Oxford BioMedica plc (the `Company`)


Holdings in Company



The Company was notified on 9 December 2005 by UBS AG (`UBS`) that following a
recent purchase, UBS had an interest in 13,319,776 of the Company`s Ordinary
Shares of 1p each, representing 3.52 per cent. of the issued Ordinary Share
capital at the close of business on 7 December 2005.

--------------------------
Oxford Biomedica PLC
09 December 2005


Oxford BioMedica plc (the `Company`)


Holdings in Company



The Company was notified on 8 December 2005 by UBS AG (`UBS`) that following a
recent purchase, UBS had an interest in 12,368,526 of the Company`s Ordinary
Shares of 1p each, representing 3.27 per cent. of the issued Ordinary Share
capital at the close of business on 7 December 2005.

----------------------------------
-----------------------------------

Oxford Biomedica PLC
24 November 2005


Oxford BioMedica plc (`the Company`)

Holding(s) in Company


The Company was notified on 23 November 2005 by Man Financial Limited (`Man`)
that following a recent purchase, funds managed by Man are interested in a total
of 24,234,535 of the Company`s Ordinary Shares of 1p each, representing 6.4 per
cent. of the issued Ordinary Share capital.

[BrauchGeld]

Hallo

Starkes Volumen und die Aktie steigt.

http://finance.yahoo.com/q?s=oxb.l

[BrauchGeld]

Hallo

Auf gehts richtung 40p ,volumen jetzt schon fast bei 5mio aktien.

http://finance.yahoo.com/q?s=oxb.l

Das will schon was heissen wenn sich die grossen der Branche (Pfizer,Merck,Biogen-Idec usw.)die Technologie von Oxford bio lizenzieren.

http://www.oxfordbiomedica.co.uk/aboutus.htm

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange.

Oxford BioMedica’s products use genes as the mediators of a therapeutic effect and/or immune response. The Company’s gene therapy products deliver therapeutic molecules in vivo whilst its gene-based immunotherapy products deliver genes that recruit the patient’s immune system to mediate a therapeutic effect. The genes are delivered by the Company’s highly engineered viral systems.

Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how. In oncology, the pipeline includes an immunotherapy and a gene therapy in multiple Phase II trials, and a preclinical targeted antibody therapy in collaboration with Wyeth. In neurotherapy, the Company`s lead product is a gene therapy for Parkinson`s disease, which is expected to enter clinical trials in 2006, and four further preclinical candidates. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field.

The Company has a staff of approximately 70 split between its main facilities in Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California. Oxford BioMedica has corporate collaborations with Arius Research, Intervet, Kiadis, MolMed, Sigma-Aldrich, Viragen and Wyeth. In addition, the Company has technology licence agreements with Biogen Idec, Merck & Co, Pfizer and a large, unnamed biopharmaceutical company.

[BrauchGeld]

Hallo

Über 16mio aktien bisher gehandelt,auch hier gibts Übernahme gerüchte.

http://finance.yahoo.com/q?s=oxb.l

[BrauchGeld]

Hallo

http://uk.finance.yahoo.com/q?d=t&p=&q=q&s=oxb&m=L

Oxford Biomedica PLC
15 December 2005


Oxford BioMedica plc (`the Company`)

Directors` Shareholdings

Following the completion of the Company`s Placing, Open Offer and Subscription
which occurred today, the Company has today been notified by those Directors of
the Company whose respective holdings in ordinary shares of 1p in the Company
(`Ordinary Shares`) has increased as a result of taking up their entitlement to
Ordinary Shares under the Open Offer as follows:

Director Increase in Resultant % of issued
Ordinary Shares holdings of share capital
Ordinary Shares

P.J. Nolan 2,000 149,738 0.03
N.L. Woolf 11,000 165,000 0.03
P.N Rodgers 12,000 22,000 0.00
R.Uppal 1 11,000 165,000 0.03

1. These Ordinary Shares are held in a self-invested pension plan

15 December 2005

[BrauchGeld]

Hallo

Top-Technologie,Top-Management,Top-Pipeline,Top-Partner und Top-Aussichten.

News Expected for 2006

2005-2006 TroVax commercial collaboration
H1 2006 TroVax Special Protocol Assessment for Phase III from FDA
H1 2006 ProSavin regulatory approval for start of Phase I/II trial
H1 2006 MetXia Phase II efficacy data in pancreatic cancer
May 2006 TroVax Phase II full report in colorectal cancer (ASCO1)
Mid 2006 TroVax Phase III trial in renal cancer to start
H2 2006 ProSavin Phase I/II trial in Parkinson’s disease to start
2006 TroVax Phase II trial in breast cancer to start (NCI2)
2006 MAb-toxin Phase I/II trial in cancer to start (Wyeth2)
2006 Canine TroVax-Vet trial in cancer to start (Intervet2)

[BrauchGeld]

Hallo

Partner dürfte bald bekannt gegeben werden.
UBS ist bei OXB.L weiterhin aktiv.

Oxford Biomedica PLC
04 January 2006


Oxford BioMedica plc (the `Company`)

Holdings in Company



The Company was notified on 3 January 2006 by UBS AG (`UBS`) that following
recent purchases, at close of business on 30 December 2005, acting through its
business group and legal entities listed below, UBS had an interest in 1
9,814,223 of the Company`s ordinary shares of 1p each, representing 3.98 per cent.
of the issued ordinary share capital.



UBS business group/legal entity Shares %
UBS AG London Branch 18,795,027 3.77
UBS Global Asset Management Life Limited 1,019,196 0.20
UBS AG - Total 19,814,223 3.98